Likewise, a shorter time to regular wheelchair use was observed in MSA patients with FGF14 expansions (median 5 years, range 2–8 years) compared with MSA cases without FGF14 expansions (median 7 years, range 4–11 years) (P = 0.02, adjusted P = 0.039). This evidence concerns the gene FGF14 and multiple system atrophy.